BridgeBio Pharma Says FDA Has Granted Breakthrough Therapy Designation To Oral Infigratinib Under Development For Children With Achondroplasia
Portfolio Pulse from Benzinga Newsdesk
BridgeBio Pharma has received Breakthrough Therapy Designation from the FDA for its oral drug Infigratinib, which is under development for treating children with achondroplasia. This designation is intended to expedite the drug's development and regulatory review.
September 17, 2024 | 11:32 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BridgeBio Pharma's Infigratinib has been granted Breakthrough Therapy Designation by the FDA, which could expedite its development and review process. This is a positive regulatory milestone for the company.
The FDA's Breakthrough Therapy Designation is a significant regulatory milestone that suggests the drug shows promise in treating achondroplasia. This can lead to faster development and review, potentially bringing the drug to market sooner, which is positive for BridgeBio Pharma's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100